GoodRx (NASDAQ:GDRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GoodRx (NASDAQ:GDRX) from a hold rating to a buy rating in a report released on Saturday.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Leerink Partners set a $5.00 target price on shares of GoodRx in a report on Thursday, August 6th. Citigroup boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $4.00 price target on shares of GoodRx in a research report on Friday, August 7th. Finally, Wells Fargo & Company increased their price target on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, GoodRx currently has an average rating of “Hold” and an average price target of $4.14.

GoodRx Stock Performance

Shares of GDRX stock opened at $3.72 on Friday. The business’s 50 day simple moving average is $3.05 and its 200 day simple moving average is $2.60. GoodRx has a one year low of $1.77 and a one year high of $5.81. The stock has a market capitalization of $1.27 billion, a PE ratio of 93.02, a PEG ratio of 1.77 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.09 EPS. As a group, research analysts forecast that GoodRx will post 0.16 earnings per share for the current year.

Institutional Trading of GoodRx

Large investors have recently modified their holdings of the stock. Essential Partners LLC lifted its position in shares of GoodRx by 375.4% during the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after acquiring an additional 11,295 shares during the period. Meridian Wealth Management LLC acquired a new stake in GoodRx in the fourth quarter worth $29,000. SG Americas Securities LLC bought a new stake in GoodRx in the first quarter valued at $29,000. Krilogy Financial LLC bought a new stake in GoodRx in the first quarter valued at $33,000. Finally, Quarry LP acquired a new position in shares of GoodRx during the third quarter valued at about $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.